LeonaBio, Inc. (LONA) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The company recently rebranded from Athira Pharma, Inc. in January 2026. Its primary assets are lasofoxifene (Phase 3 for breast cancer) and ATH-1105 (Phase 2 ready for ALS). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(32,948) | $(9,143) |
| Net Loss Per Share (Basic & Diluted) | $(1.73) | $(2.34) |
| Operating Expenses | $17,214 | $9,536 |
| Cash, Cash Equivalents & Investments | $67,679 | $71,209 (Dec 31, 2025) |
| Net Cash Used in Operating Activities | $(20,903) | $(14,665) |
| Accumulated Deficit | $(544,703) | $(415,289) |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by $23.8 million (260%) compared to Q1 2025. This was primarily driven by a $16.3 million non-cash loss related to the change in fair value of the Sermonix pre-funded warrant prior to its reclassification to equity.
- R&D Expenses: Research and development expenses increased by $6.9 million (162%) to $11.3 million. This increase was driven by $8.6 million in costs associated with the newly in-licensed lasofoxifene program, offset by decreases in costs for fosgonimeton and ATH-1105.
- Balance Sheet Shifts: Total liabilities decreased significantly from $64.4 million to $22.3 million due to the reclassification of the $37.5 million Sermonix pre-funded warrant from a liability to equity following stockholder approval in March 2026.
- Stock Split: All share and per-share amounts have been restated to reflect a 1-for-10 reverse stock split completed in September 2025.
Guidance, Outlook, and Risks
- Liquidity: Management estimates that existing cash, cash equivalents, and investments of $67.7 million are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring significant losses.
- Capital Raising Constraints: The company is currently ineligible to use Form S-3 for registered offerings through December 2026 due to a failure to timely file a Form 8-K. This limits the ability to raise capital via its At-The-Market (ATM) facility or other expedited registered offerings.
- Pipeline Progress: The company is advancing the Phase 3 ELAINE-3 trial for lasofoxifene and preparing for Phase 2 trials for ATH-1105. Development of fosgonimeton was paused following negative Phase 2/3 results.
- Key Risks:
- Failure of clinical trials to demonstrate safety or efficacy.
- Inability to raise additional capital on favorable terms due to S-3 ineligibility.
- Regulatory delays or denials.
- Reliance on third-party manufacturers and CROs.
Investor Verification Checklist
- Verify the timeline for regaining Form S-3 eligibility and the impact on future fundraising capabilities.
- Confirm the enrollment status and data readout timeline for the lasofoxifene Phase 3 ELAINE-3 trial.
- Review the specific terms of the Sermonix license agreement and any remaining milestone payment obligations ($14.2 million liability recorded).
- Assess the burn rate relative to the $67.7 million cash position to validate the 12-month runway estimate.
- Monitor the status of the PIPE financing registration statement effectiveness and potential liquidated damages if maintenance fails.